Implants and methods for treating inflammation-mediated conditions of the eye

• US 8,242,099 B2
• Filed: 10/12/2011
• Issued: 08/14/2012
• Est. Priority Date: 07/05/2000
• Status: Expired due to Term

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Wong, Vernon G., Hu, Mae W. L.
• Primary Examiner(s): Foley, Shanon A
• Application Number:
  US13/271,451
• Publication Number:
  US 20120035146A1
• Time in Patent Office: 307 Days
• Field of Search: None
• US Class Current: 514/174
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 5/38 of the suprarenal hormones

Abstract

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.

Claims

1. A bioerodible implant for treating an inflammation-mediated condition of the eye, the implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, the implant structured to be placed in the vitreous of the eye and deliver the agent to the vitreous in an amount sufficient to reach an in vivo concentration equivalent to at least 0.05 μ

g/mL dexamethasone within about 48 hours and to maintain an in vivo concentration equivalent to at least 0.03 μ

g/mL dexamethasone for at least about three weeks.

2. The implant of claim 1, wherein the steroidal anti-inflammatory agent is selected from the group consisting of methylprednisolone, prednisolone, prednisone, prednisolone 25-diethylamino-acetate, betamethasone, beclomethasone, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, and triamcinolone hexacetonide.

3. The implant of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.

4. The implant of claim 1, wherein the steroidal anti-inflammatory agent comprises about 10 to 90% by weight of the implant.

5. The implant of claim 1, wherein the steroidal anti-inflammatory agent comprises about 50 to about 80% by weight of the implant.